PO Box 1488
Warrenville, IL 60555
Phone: 331.248.7888
Email: sidp@affinity-strategies.com
Promoting evidence-based antimicrobial stewardship for patients with immunocompromising conditions can be tricky when they’re often excluded from clinical studies. Dr. Zahra Kassamali Escobar (@ZKEPharmD) explores this gray zone with Dr. Catherine Liu and Dr. Justine Ross (@abella_ross)
References:
Fluoroquinolone Prophylaxis
- Bucaneve et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353:977-87. DOI: 10.1056/NEJMoa044097
- Cullen et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353:988-98. DOI: 10.1056/NEJMoa050078
- Drayson et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicenter, double-blind, placebo-controlled, randomized, phase 3 trial. Lancet Oncology 2019; 20(12):1760-72. DOI: 10.1016/S1470-2045(19)30506-6
- Satlin et al. Colonization with fluoroquinolone-resistant enterobacterales decreases the effectiveness of fluoroquinolone prophylaxis in hematopoietic cell transplant recipients. Clin Infect Dis 2021 May 6. doi: 10.1093/cid/ciab404.
Antibiotic Treatment and Microbiome Implications
- Aguilar-Guisado M, et al. Optimisation of empirical antimicrobial therapy in patients with haemotological malignancies and febrile neutropenia (How Long study): an open-label, randomized, controlled, phase 4 trial. Lancet Haematol. 2017 Dec;4(12):e573-83. doi: 10.1016/S2352-3026(17)30211-9.
- Shono et al. Gut microbiome injury in allogeneic haematopoietic stem cell transplantation. Nat Rev Cancer. 2018;18(5):283-95. doi: 10.1038/nrc.2018.10.
- Weber et al. Microbiome disruption induced by early use of broad-spectrum antibiotics is an independent risk factor of outcome after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(5):845-52. doi: 10.1016/j.bbmt.2017.02.006
- Pinato et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019;5(12):1774-78. doi:10.1001/jamaoncol.2019.2785
Catherine Liu PharmD, BCPS, BCGP
Dr. Catherine Liu is an infectious diseases physician, professor at the Fred Hutchinson Cancer Research Center, and an associate professor at the University of Washington. She is the director of the antimicrobial stewardship and outpatient parenteral antimicrobial therapy programs as well as an associate director of infection prevention at the Seattle Cancer Alliance. Prior to moving to Seattle, Dr. Liu was a medical director of infection prevention and the infectious disease management program at University of California, San Francisco. Her clinical and research interests include infections in immunocompromised hosts focusing on those with cancer and hematopoietic stem cell transplant recipients, implementation and evaluation of strategies to optimize antimicrobial use, and prevention of healthcare associated infections. She is also known for her work and authorship on the IDSA MRSA treatment guidelines and the vancomycin therapeutic drug monitoring guidelines.
Justine Ross PharmD, BCIDP
Dr. Justine Ross is an infectious diseases clinical pharmacist specialist at the City of Hope National Medical Center in Southern California and the co-chair of the antimicrobial stewardship program. She completed a PGY-1 Acute Care Pharmacy residency and a PGY-2 Infectious Diseases residency at University of California San Diego Health. Her current work includes enhancing electronic medical records workflows to incorporate pharmacists in antimicrobial stewardship practices, updating policies and procedures to ensure appropriate anti-infective use, and involvement in pharmacy, therapeutics, and infection control committees. Dr. Ross’ research interests include antimicrobial stewardship practices in solid tumor and hematologic malignancy populations and studying the impact and outcomes of anti-infective prophylaxis in immunocompromised populations.
